NASDAQ OMX

Skybox Security Raises $150 Million Led by CVC Capital Partners' Growth Fund With Participation from Pantheon

Dela

SAN JOSE, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today the company signed a definitive agreement to receive a $150 million growth equity investment led by CVC Capital Partners' Growth Fund (CVC Growth) for $100 million, with participation from Pantheon for $50 million. CVC Capital Partners is a leading private equity and investment advisory firm, and Pantheon is a prominent global investor in private equity, infrastructure and real assets. 

Based in Silicon Valley, Skybox has a compound annual growth rate (CAGR) of 46 percent and positive cash flow (2014 ­- 2016). This round of funding will enable an accelerated investment in sales and marketing, customer care and R&D. It will also be used for potential M&A activity, to capitalize on the approximately $10 billion market opportunity in cybersecurity management.

Skybox builds best-in-class cybersecurity management software that gives customers comprehensive visibility of their unique attack surface. The software uses analytics to prioritize an organization's risk exposures and recommend informed action to best address those exposures. These capabilities extend across highly complex networks, including those in physical, virtual, cloud and operational technology (OT) environments. The company's broad platform, the Skybox(TM) Security Suite, enables organizations to reduce security risks that attackers can find and exploit, such as device misconfigurations and policy violations, as well as exposed and unpatched vulnerabilities.

"Skybox's track record is impressive and there is clear demand for their solutions," said Jason Glass, senior managing director of CVC Growth Partners. "It is a true leader in cybersecurity management, helping organizations better protect themselves and become more efficient. Gidi Cohen, Skybox's co-founder and CEO, is a respected innovator in security management and analytics, and we look forward to working with him and the wider executive team as we expand Skybox's offering and global reach."

The demand for Skybox's solutions has been increasing due to a maturing cybersecurity market and the desire among security leaders to more efficiently manage security programs and gain better ROI from existing technologies. In the first half of 2017, for example, Skybox showed a 62 percent increase in sales and 59 percent increase in product transactions compared to the same period last year (January 1 - June 30).

"Enterprises, governments... everyone is either embarking on or going through massive digital transformation, and this means new challenges for security because the attack surface of these organizations is growing more complex," said Skybox CEO Gidi Cohen. "We've been consistently evolving our technology to meet those challenges. With this investment, we'll accelerate that innovation, focusing on some of the most critical areas, such as security management for the cloud and the OT networks that control critical infrastructure."

Skybox customers are Global 5000 companies and government agencies, in more than 50 countries and nearly every industry. The company's products are used by six of the top 10 global banks, 10 global telecommunications firms, five of the world's largest consumer goods manufacturers and 10 of the largest energy providers globally.

Jason Glass and John Clark, managing partner of CVC Growth Partners, will join Skybox's board of directors. CVC Growth has secured total equity commitments of $1 billion and invests primarily in North America and Europe, focusing on high growth software and technology­-enabled services businesses in a variety of sectors, including security, cloud computing, mobility, compliance, payments, financial technology and vertical software.

About Skybox Security
www.skyboxsecurity.com
Skybox arms security leaders with the broadest set of solutions for cybersecurity management. By integrating with more than 120 networking and security technologies, the Skybox(TM) Security Suite provides the context needed for informed and timely action, combining attack vector analytics and advanced threat intelligence to continuously analyze vulnerabilities in your environment and correlate them with exploits in the wild. This gives the insight needed to improve and automate security operations in vulnerability and threat management and firewall and security policy management in physical, virtual and cloud environments. 

© 2017 Skybox Security, Inc. All rights reserved. Skybox Security and the Skybox Security logo are either registered trademarks or trademarks of Skybox Security, Inc., in the United States and/or other countries. All other trademarks are the property of their respective owners. Product specifications subject to change at any time without prior notice.

CONTACT INFORMATION

Skybox Security

Tawnya Lancaster
Director of Brand and Communications
408.205.1618 | Tawnya.lancaster@skyboxsecurity.com

OneChocolate for Skybox Security

North America: Brian Blank
1-415-606-8381 | brianb@onechocolatecomms.com

United Kingdom: Daniel Couzens
+44 (0)20 7437 0227 | DanielC@onechocolatecomms.co.uk

Germany: Melanie Grasser
+49 (0)89 3888 920 10 | MelanieG@onechocolatecomms.de

France: Xavier Delhôme
+33 1 41 31 75 09 | xavier@onechocolate.fr

CVC Capital Partners

Carsten Huwendiek, Head of Communications
Tel: +44 20 7420 4240
Email: chuwendiek@cvc.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Skybox Security via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29Pressmeddelande

Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre

Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30Pressmeddelande

SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be

Corline Biomedical AB: Corline erhåller andra utbetalningen från EU-kommissionen31.7.2018 08:45Pressmeddelande

Corline Biomedical AB ("Corline") meddelade i november 2016 att EU-kommissionen beslutat anslå ca 2,4 MEUR (ca 23,1 MSEK) till bolagets kliniska studie inom njurtransplantation med läkemedelskandidaten Renaparin ® . En första utbetalning från H2020-programmet till Corline om ca 1,2 MEUR genomfördes i mars 2017. Corline har nu sammanställt en rapport till EU-kommissionen i vilken framgår att samtliga delmål i projektets första fas är uppnådda. Därmed har kommissionen beslutat om fortsatt stöd och en andra delbetalning om ca 1 MEUR utbetalas inom kort. Corline erhåller anslaget för att genomföra den planerade kliniska fas 1-studien för Renaparin® som är under utveckling för att förbättra njurtransplantation. Den första projektfasen har bland annat innefattat GMP-produktion av läkemedelssubstansen och upprättande av ansökan om klinisk prövning samt inlämnande av densamma till Läkemedelsverket. Samtliga delmål i den första projektfasen har uppfyllts och rapporteringen om dessa har nu grans

RFA Accelerates Growth with Expansion in Luxembourg30.7.2018 15:00Pressmeddelande

RFA announces new private financial cloud in Luxembourg to accelerate growth and accommodate increased demand in technology regulation and cybersecurity LUXEMBOURG, July 30, 2018 (GLOBE NEWSWIRE) -- RFA, a next-gen managed IT service provider for the financial industry, announces a new private financial cloud in Luxembourg. This expansion allows RFA to accommodate accelerated growth in Europe and offer a portfolio of high quality private cloud services to both its existing and new financial services clients in Luxembourg, Madrid, Paris, and the wider region. Along with the London office, the new office doubles RFA's footprint in Europe and further bolsters the company's growth strategy. RFA has two highly secure, tier-one data centres in Luxembourg which meet the ISO27001 and SSAE16/Type II standards, which is key for firms regulated by the Commission de Surveillance du Sector Financier (CSSF). RFA is now ideally placed to provide a range of services to clients in this region, and offe

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum